Verrica Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
YCANTH sales and international expansion underpin the commercial business, while common-warts Phase III readouts are expected in Q1 and mid-2027. VP-315 is advancing toward Phase III as a potential nonsurgical BCC treatment.
-
YCANTH achieved strong sequential growth in both revenue and units, supported by improved prescriber targeting and patient access. A new $27.5 million credit facility extends cash runway into 2028, while pivotal trials for common warts and VP-315 in basal cell carcinoma advance on schedule.
-
YCANTH has seen improved access and growing adoption, with Q1 revenue at $4.3 million and over 100,000 applicator units dispensed. The pipeline includes a phase III common warts program (50% enrolled) and a BCC program with strong phase II results. Cash runway extends into Q1 2027.
-
YCANTH has achieved strong commercial growth with expanding market penetration and robust support programs. International expansion is progressing, and the pipeline includes a large common warts program and a promising basal cell carcinoma candidate, VP-315, with significant clinical and commercial potential.
-
Q1 2026 saw record growth in YCANTH demand, with revenue up 25% year-over-year and strong momentum into Q2. The company advanced its clinical pipeline, launched YCANTH in Japan, and is preparing for EU expansion, while maintaining a solid cash position to fund operations into 2027.
-
YCANTH continues to drive revenue growth through expanded access and clinician adoption, with a robust pipeline targeting common warts and basal cell carcinoma. Phase III trials for both indications are progressing, supported by strong financials and strategic partnerships.
-
YCANTH has rapidly gained adoption by addressing a major unmet need in molluscum contagiosum, with expanded access, streamlined distribution, and a growing, collaborative sales force. The pipeline includes a phase III program for common warts and a promising Basal Cell Carcinoma candidate, supporting long-term growth.
Fiscal Year 2025
-
2025 marked a transformative year with revenue up 368% year-over-year, driven by YCANTH growth, cost reductions, and pipeline progress. Debt was retired, cash runway extended into 2027, and global expansion advanced, positioning for further growth in 2026.
-
Q3 revenue was $14.3M, including $10.7M in Torii milestone and collaboration revenue; non-GAAP net income was $1.2M. YCANTH dispensed units grew 120% YoY for 9M, while Phase 3 plans advanced for common warts and VP-315.
-
A commercial-stage dermatology company reported strong growth for its FDA-approved molluscum treatment, expanded access, and robust insurance coverage. Key pipeline assets include a phase III-ready program for common warts and a late-stage candidate for basal cell carcinoma, both addressing large markets.
-
Q2 2025 saw record YCANTH growth, a major Torii partnership expansion, and a return to profitability. Revenue rose to $12.7M, driven by milestone payments and strong commercial execution, with further growth and milestone payments expected in the second half of 2025.
-
The company is driving growth with its dermatology product YCANTH, achieving strong clinical results and expanding market access through improved reimbursement and distribution. Financially, it is targeting operational break-even by year-end, supported by a robust pipeline and upcoming milestones.
-
Q1 2025 saw 16.7% sequential growth in YCANTH units and $3.4M revenue, with improved margins and reduced expenses. Cash runway depends on milestone payments or warrant exercises, while clinical and commercial momentum continues in both dermatology and oncology.
-
A new commercial strategy and management team have driven sequential growth for an FDA-approved molluscum treatment, with expanded insurance coverage and physician adoption. Pipeline programs for common warts and basal cell carcinoma are advancing, supported by strong partnerships and financial discipline.
-
A major restructuring and commercial strategy shift have driven improved sales and operational efficiency, with Ycanth gaining traction in the molluscum market. Pipeline progress includes a global phase 3 program for common warts and promising phase 2 results in basal cell carcinoma.
-
New leadership has restructured operations, secured funding, and implemented a focused commercial strategy for YCANTH, targeting both dermatologists and pediatricians. Pipeline expansion includes a global phase III program for common warts and promising data for VP-315 in basal cell carcinoma.
Fiscal Year 2024
-
Q4 2024 saw a successful turnaround with cost reductions, sequential growth in YCANTH units, and a $42M capital raise. Full-year revenue rose to $7.6M, with strong gross margins and expanding pediatric adoption. Cash runway depends on milestone payments and prudent management.
-
Promising phase II data for VP-315 in basal cell carcinoma positions it as a non-invasive alternative to surgery, with expansion potential into squamous cell carcinoma. YCANTH's launch faces logistical hurdles but maintains strong coverage and physician support, while market opportunities in molluscum and warts remain significant.
-
Q2 2024 saw $5.2M in revenue, driven by YCANTH growth and expanded coverage, while a key settlement is expected to boost demand as compounded cantharidin exits the market. Positive Phase 2 data for VP-315 in basal cell carcinoma highlight future pipeline potential.
-
Q1 revenues rose to $3.2M, driven by increased demand and expanded coverage. The launch of YCANTH, the first FDA-approved molluscum treatment, is supported by a growing sales force and improved reimbursement, with a 42% uptick in buy-and-bill accounts after J-Code publication.